<div id="readability-page-1"><p>Signal Advisors Wealth LLC decreased its holdings in  Amgen Inc. (NASDAQ:AMGN - Free Report) by 51.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor  owned 3,074 shares of the medical research company's stock after selling 3,226 shares during the quarter. Signal Advisors Wealth LLC's holdings in Amgen were worth $867,000 at the end of the most recent quarter.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>A number of other hedge funds have also added to or reduced their stakes in AMGN. Fairvoy Private Wealth LLC boosted its position in shares of  Amgen by 1.1% during the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock valued at $885,000 after buying an additional 35 shares during the last quarter.  Nicholson Wealth Management Group LLC lifted its stake in  Amgen by 0.6% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock valued at $1,652,000 after acquiring an additional 35 shares in the last quarter.  Crumly &amp; Associates Inc. boosted its holdings in  Amgen by 3.2% during the 2nd quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock worth $320,000 after acquiring an additional 36 shares during the last quarter.  Maryland Capital Advisors Inc. boosted its holdings in  Amgen by 5.2% during the 2nd quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock worth $204,000 after acquiring an additional 36 shares during the last quarter.  Finally, Lion Street Advisors LLC grew its stake in shares of  Amgen by 1.3% in the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock worth $774,000 after acquiring an additional 36 shares in the last quarter. Institutional investors and hedge funds own  76.50% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>AMGN has been the subject of a number of research analyst reports. Erste Group Bank raised Amgen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, December 5th. Scotiabank assumed coverage on Amgen in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $385.00 price objective on the stock. Citigroup raised their target price on Amgen from $310.00 to $315.00 and gave the company a &#34;neutral&#34; rating in a research report on Wednesday, September 24th. DZ Bank lifted their target price on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Finally, Truist Financial began coverage on shares of Amgen in a report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 price target on the stock. One research analyst  has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one  has issued  a Sell rating to the company. According to MarketBeat.com, Amgen currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $332.85.</p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p><b>Check Out Our Latest Analysis on AMGN</b></p><h2>Amgen Price Performance</h2><p>AMGN stock opened at $327.38 on Friday. The firm has a 50 day moving average of $319.32 and a 200-day moving average of $300.20. The firm has a market capitalization of $176.29 billion, a P/E ratio of 25.30, a price-to-earnings-growth ratio of 2.96 and a beta of 0.45. Amgen Inc. has a 12 month low of $257.05 and a 12 month high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. </p><ul><li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li></ul><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the business posted $5.58 earnings per share. The firm's revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.  As a group, sell-side analysts predict that  Amgen Inc. will post 20.62 earnings per share for the current fiscal year. </p><h2>Amgen Increases Dividend</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a boost from Amgen's previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. Amgen's dividend payout ratio  is 73.57%. </p><h2>Insider Transactions at Amgen</h2><p>In related news, EVP Murdo Gordon sold 6,879 shares of the firm's stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company's stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business's stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company's stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is owned by corporate insiders. </p><h2>Amgen Profile</h2> (Free Report)<p>Amgen Inc <span>NASDAQ: AMGN<span></span></span> is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.  </p><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p><h2>Read More</h2><ul><li>Five stocks we like better than Amgen</li><li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li><li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li><li>How to Calculate Inflation Rate</li><li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li><li>Roth IRA Calculator: Calculate Your Potential Returns</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Signal Advisors Wealth LLC reduced its holdings in Amgen Inc. by 51.2% in Q3, now valued at $867,000. Other hedge funds adjusted their stakes in Amgen. Analysts have varied ratings, with an average "Moderate Buy" and target price of $332.85. Amgen's Q3 earnings beat estimates, with $5.64 EPS and $9.56 billion revenue. The company increased its dividend and set FY 2025 EPS guidance at 20.600-21.400.</p>

Signal Advisors Wealth LLC Has $867,000 Stock Holdings in Amgen Inc. $AMGN